Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants:

Slides:

Advertisements

Similar presentations

When Should a Clinical Trial Design with Pre-Stratification be Used? Group 1.

Advertisements

K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.

Challenges When Conducting Economic Evaluation Alongside Clinical Trials: Experience Of Economic Appraisal In Cardiovascular Disease Andrew Briggs University.

Model Checking in the Proportional Hazard model

Cox Proportional Hazards Regression Model Mai Zhou Department of Statistics University of Kentucky.

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

R Ferrari, WJ Remme, M Simoons, M Bertrand, K FOX, On behalf of the EUROPA investigators. A sub study of PERTINENT PER indopril – T hrombosis, I nflammatio.

Published in Circulation 2003 Rory Hachamovitch, MD, MSc; Sean W. Hayes, MD; John D. Friedman, MD; Ishac Cohen PhD; Daniel S. Berman, MD Comparison of.

Review of an article Not all Angiotension-Converting Enzyme (ACE) inhibitors are Equal: Focus on Ramipril and Perindopril DiNicolantonio J, Lavie C, O’Keefe.

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:

Impact of ACE inhibitors and Angiotensin II receptor blockers on all- cause mortality in hypertension trials Congress of the European Society of Cardiology.

Lecture 12: Cox Proportional Hazards Model

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?

Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

Short- and Long-Term Mortality After Myocardial Infarction in Patients With and Without Diabetes Featured Article: Sjoerd T. Nauta, M.S.C., Jaap W. Deckers,

Prognostic value of coronary artery calcium screening in asymptomatic smokers and non-smokers by Leslee J. Shaw, Paolo Raggi, Tracy Q. Callister, and Daniel.

Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Nuisance Bleeding With Prolonged Dual Antiplatelet.

Multivariate associations* between selected covariates and statin use Jawahar L. Mehta, et al. Am J Cardiol 2006;98:923–928.

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/AHA 2011 Expert Consensus Document on Hypertension.

Christopher P. Cannon, M. D. , Eugene Braunwald, M. D. , Carolyn H

US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Long-Term Forecasting and Comparison of Mortality in the Evaluation of the Xience Everolimus-Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness.

Comparison of the Short-Term Survival Benefit Associated With Revascularization Compared With Medical Therapy in Patients With No Prior Coronary Artery.

by Qi Sun, Monik C. Jiménez, Mary K. Townsend, Eric B. Rimm, JoAnn E

Incremental Value of the CRUSADE, ACUITY, and HAS‐BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients.

Excessively High Hydration Volume May Not Be Associated With Decreased Risk of Contrast‐Induced Acute Kidney Injury After Percutaneous Coronary Intervention.

Circ Cardiovasc Qual Outcomes

by John T. Wilkins, Hongyan Ning, Neil J. Stone, Michael H

Prediction of Cardiovascular Disease by the Framingham‐REGICOR Equation in the High‐Risk PREDIMED Cohort: Impact of the Mediterranean Diet Across Different.

RAAS Blockade: Focus on ACEI

Neil J. Stone et al. JACC 2014;63:

on behalf of the LEADER Trial Steering Committee and Investigators

Diabetes hazard rates by number of visits with reported statin use.

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Fung TT, et al. Circulation 2009;119:

Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies

Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.

Contemporary Evidence-Based Guidelines

Risk Stratification and Interventional Cardiology: Robert L

ASCORE : An up-to-date cardiovascular risk score for hypertensive patients reflecting. contemporary clinical practices developed. using the ASCOT trial.

Potential mechanisms whereby statins may reduce the risk of stroke

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

(A) Illustration of the receiver operating characteristic (ROC) curve (discrimination) of the recalibrated model on the external validation set data. (A)

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

These slides highlight a report from a Hotline Session and a Satellite symposium held at the European Society of Cardiology Congress, 2003 in Vienna Austria,

Characteristics of 21,484 Patients With MI Who Survived for >30 Days After Discharge, by Calendar Year - Part I Soko Setoguchi, et al. J Am Coll Cardiol.

Baseline Characteristics of the Subjects*

Effects of Pay-for-Performance on the Quality of Primary Care in England Mean Scores for Clinical Quality at the Practice Level for Aspects of Care for.

Baseline Characteristics

Figure 4 Laquinimod treatment suppresses development of spontaneous EAE Laquinimod treatment suppresses development of spontaneous EAE (A) 2D2 × Th mice.

(A) Multivariable Cox regressions showing the association of higher CHA2DS2-Vasc scores (≥6) and (B) R2CHA2DS2-Vasc scores (≥7) with 1-year mortality (CABG,

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

International Journal of Cardiology

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

The estimated survival function using the Cox proportional hazards model and the mean value covariate pattern (days to recurrence, net tumor volume) for.

Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes Steven M. Brunelli, Ravi Thadhani,

Frankel DS, et al. J Am Coll Cardiol. 2009;53:754-62

Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.

Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.

Detecting Treatment by Biomarker Interaction with Binary Endpoints

Nonlinear associations between anxiety-depression and SA of the genetic cluster 6R. Nonlinear associations between anxiety-depression and SA of the genetic.

Presentation transcript:

Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model by Rohit M. Oemrawsingh, K. Martijn Akkerhuis, Laura C. Van Vark, W. Ken Redekop, Goran Rudez, Willem J. Remme, Michel E. Bertrand, Kim M. Fox, Roberto Ferrari, A.H. Jan Danser, Moniek de Maat, Maarten L. Simoons, Jasper J. Brugts, Eric Boersma, and J Am Heart Assoc Volume 5(3):e002688 March 28, 2016 © 2016 Rohit M. Oemrawsingh et al.

Clinical risk score distribution. Clinical risk score distribution. The mean value of the clininal risk score (N=8726) was of 7.67±2.83. Rohit M. Oemrawsingh et al. J Am Heart Assoc 2016;5:e002688 © 2016 Rohit M. Oemrawsingh et al.

Absolute risks of the primary endpoint across different clinical (X‐axis) and pharmocogenetic risk strata (Panels A through D). Absolute risks of the primary endpoint across different clinical (X‐axis) and pharmocogenetic risk strata (Panels A through D). P values were derived from multivariate Cox proportional hazards regression models fitted with the following covariates: clinical risk score; PGXscore; treatment; and treatment×PGXscore interaction. PGXscore indicates pharmacogenetic risk score. Rohit M. Oemrawsingh et al. J Am Heart Assoc 2016;5:e002688 © 2016 Rohit M. Oemrawsingh et al.

Absolute risk reduction (Y‐axis on a 0 to 1 scale) by perindopril across different levels of clinical (X‐axis) and pharmacogenetic risk. Absolute risk reduction (Y‐axis on a 0 to 1 scale) by perindopril across different levels of clinical (X‐axis) and pharmacogenetic risk. PGXscore indicates pharmacogenetic risk score. Rohit M. Oemrawsingh et al. J Am Heart Assoc 2016;5:e002688 © 2016 Rohit M. Oemrawsingh et al.

Observed versus estimated risks according to the clinical and combined (full) risk prediction models. Observed versus estimated risks according to the clinical and combined (full) risk prediction models. P values were derived from Hosmer‐Lemeshow goodness‐of‐fit test. Rohit M. Oemrawsingh et al. J Am Heart Assoc 2016;5:e002688 © 2016 Rohit M. Oemrawsingh et al.